Morgan Stanley Keeps Exelixis Equal-Weight, Raises Target to $60
Morgan Stanley maintained its Equal-Weight rating on Exelixis and raised its price target to $60 from $53. The target implies 9.4% downside from the Oct. 29 close of $66.20.
Related stories
US session market picture: S&P 500 -2.13%, Nasdaq 100 -3.87%; EUR/USD -0.09%, WTI +1.43%, INTC leads volume
US session market picture. US index futures: S and P futures is down 2.13 percent, Nasdaq futures is down 3.87 percent, Dow futures is down 1.32 percent and Russell futures is down
M impact | EQUITY | Oct 30, 2026, 07:30 PM UTC
Alphabet Convertible Preferred Yield Tops 7.5%
Alphabet’s mandatory convertible preferred stock, issued as part of its $85 billion equity capital-raising plan in June, has fallen alongside the company’s common stock and now yie
H impact | EQUITY | Oct 30, 2026, 07:25 PM UTC
JioStar Q2 Profit Falls 13% Amid Weak Advertising Environment
Reliance Industries' entertainment subsidiary reported September-quarter revenue up 10% year on year to Rs. 6,806 crore and EBITDA down nearly 14% to Rs. 1,502 crore. Profit after
M impact | EQUITY | Oct 30, 2026, 07:18 PM UTC
Nasdaq Near Session Lows Approaching Close
The Nasdaq remained near session lows approaching the close.
M impact | EQUITY | Oct 30, 2026, 07:16 PM UTC
Eli Lilly and AbbVie shares hit records after earnings and outlook increases
Shares of Eli Lilly and AbbVie reached new highs Friday after both companies reported stronger-than-expected third-quarter earnings and raised their full-year 2026 outlooks. Lilly
H impact | EQUITY | Oct 30, 2026, 07:14 PM UTC
First Industrial Realty Trust Shares Fall 1.2% After JPMorgan Downgrade
First Industrial Realty Trust shares were down 1.2% after JPMorgan downgraded the stock.
M impact | EQUITY | Oct 30, 2026, 07:13 PM UTC